Aura Biosciences Inc Total Assets
Aura Biosciences Inc total assets. Based on the latest financial reports, Aura Biosciences Inc (AURA) holds total assets worth $137.68 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AURA stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Aura Biosciences Inc (2019–2025)
Total assets of Aura Biosciences Inc from 2019 to 2025. This chart illustrates how Aura Biosciences Inc's total assets have evolved over time, based on quarterly financial data. See AURA share price today for real-time trading data and today's change.
Aura Biosciences Inc - Asset Composition Analysis
Aura Biosciences Inc Total Assets Breakdown (December 2025)
Aura Biosciences Inc total assets breakdown as of December 2025. Aura Biosciences Inc's total assets of $137.68 Million consist of 88.4% current assets and 11.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 35.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Aura Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Aura Biosciences Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aura Biosciences Inc's current assets represent 88.4% of total assets in 2025, a decrease from 90.0% in 2019.
- Cash Position: Cash and equivalents constituted 35.1% of total assets in 2025, down from 87.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Aura Biosciences Inc Competitors by Total Assets
Key competitors of Aura Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Aura Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.09 | 11.06 | 17.47 |
| Quick Ratio | 7.09 | 11.06 | 17.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $101.80 Million | $122.35 Million | $87.56 Million |
Aura Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Aura Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.39 |
| Latest Market Cap to Assets Ratio | 3.75 |
| Asset Growth Rate (YoY) | -7.2% |
| Total Assets | $169.43 Million |
| Market Capitalization | $634.79 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Aura Biosciences Inc's assets at a significant premium (3.75x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Aura Biosciences Inc's assets decreased by 7.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Aura Biosciences Inc (2019–2025)
The table below shows the annual total assets of Aura Biosciences Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $169.43 Million | -7.16% |
| 2024-12-31 | $182.50 Million | -28.45% |
| 2023-12-31 | $255.07 Million | +13.91% |
| 2022-12-31 | $223.94 Million | +39.93% |
| 2021-12-31 | $160.03 Million | +623.99% |
| 2020-12-31 | $22.10 Million | -40.35% |
| 2019-12-31 | $37.05 Million | -- |
About Aura Biosciences Inc
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the … Read more